1 - Preventing the spread of drug-resistant bacteria : Rapid molecular assays »

1.1 - BD GeneOhm™ MRSA     1.1 - BD GeneOhm™ MRSA

Because time makes all the difference...

Related Documents
Related Links

The BD GeneOhm™ MRSA test is the first rapid, molecular-based assay cleared by the FDA, Health Canada and bearing the CE Mark for the direct detection of methicillin- resistant Staphylococcus aureus (MRSA) from a nasal specimen. Test procedure time for the assay is under two hours. Compared to culture methods requiring two to five days, this rapid turn-around time can be used to enhance any infection control program. The test provides a definitive result in a single assay.

The BD GeneOhm™ MRSA test enables hospitals to dramatically improve the identification of MRSA, which can effectively result in the prevention and control of MRSA infections.

  • Rapid turnaround time
  • Clinical performance
  • Can help to dramatically reduce healthcare costs
  • Simple use directly from nasal swab
  • Adaptable and easily incorporated into existing lab workflow

1.2 - BD GeneOhm™ StaphSR     1.2 - BD GeneOhm™ StaphSR

Related Documents
Related Links

Assay Features: 

  • Rapid, simultaneous detection and differentiation of MRSA and SA direct from positive blood culture bottles, wounds and nasal specimens.
  • Results in less than 2 hours vs. 2-3 days required for traditional microbiology culture methods
  • Simple user-friendly workflow
  • Aids in the differentiation of MRSA/SA and potential contaminants such as coagulase negative Staphylococcus.

Clinical Advantages:

  • Rapid identification and treatment of BSIs has been proven to reduce healthcare costs and improve patient outcomes
  • Promotes faster, better antibiotic selection to prevent the emergence of vancomycin resistant organisms
  • Facilitates earlier isolation of patients infected with MRSA to prevent further transmission and infection

1.3 - BD GeneOhm™ VanR     1.3 - BD GeneOhm™ VanR

Related Documents
Related Links

Assay Features:

  • Lab results in <2 hours for vancomycin resistance
  • Aids in the rapid identification and differentiation of both vanA and vanB genes direct from perianal and/or rectal swabs
    • vanA and vanB are clinically relevant genes associated with vancomycin-resistant enterococci.
    • These genes are transferrable from organism to organism
  • Simple, user-friendly work flow
    • Less time and labour required when compared to traditional culture method.

Clinical Advantages:

  • Rapid identification of vancomycin-resistant organisms
  • Facilitates early infection control intervention to prevent transmission and infection
  • Prevention of VRE transmission and infection can save healthcare costs by decreasing hospital length of stay and the need for contact precautions

1.4 - BD GeneOhm™ CDiff     1.4 - BD GeneOhm™ CDiff


Related Documents
Related Links

The Answer You Need Today
From a Single Test Result

Assay Features

  • Performance comparable to the "gold standard" cytotoxicity assay
  • Real-time PCR results in <2 hours for toxigenic C. difficile
  • Specific detection of the tcdB gene found only in toxigenic C. difficile
  • One single method that can replace current C. difficile testing

Clinical Advantages

  • Rapid, sensitive and specific results for patients suspected of having C. difficile infection (CDI)
  • Earlier accurate diagnosis enables appropriate treatment of infected patients and can help avoid empiric treatment and unnecessary exposure to antibiotics in negative patients
  • Facilitates targeted infection control practices to prevent transmission and infection.